Human immunodeficiency virus type 1 Gag-Pol-Nef-Env antigens (HIV-1 Gag-Pol-Nef-Env)

This target refers to a multi-antigen approach used in HIV-1 immunotherapy and vaccine development, focusing on the expression of four key viral proteins: Gag, Pol, Nef, and Env. Gag (group-specific antigen) provides structural components like the capsid (UniProt: P04591); Pol (polymerase) encodes essential enzymes including reverse transcriptase, protease, and integrase (UniProt: P03366); Nef (negative regulatory factor) is an accessory protein involved in immune evasion by downregulating MHC-I (UniProt: P04601); and Env (envelope) facilitates viral entry into host cells via gp120 and gp41 (UniProt: P04578). By expressing these antigens, the goal is to prime the host's adaptive immune system—specifically cytotoxic T lymphocytes (CTLs) and B cells—to recognize and destroy HIV-infected cells or neutralize the virus (PubMed: 19027482). This strategy aims to overcome the high mutational rate of HIV by targeting multiple conserved and immunodominant epitopes simultaneously. Clinical applications include both preventive vaccines, such as the RV144 trial which used Env and Gag/Pol (NEJM: 2009; 361:2209-2220), and therapeutic interventions designed to achieve functional cure or improved viral suppression in infected individuals. However, challenges remain, as seen in the STEP trial where an Ad5-vectored Gag/Pol/Nef vaccine was associated with increased infection risk in certain populations (Lancet: 2008; 372:1881-1893).

Other names

HIV-1 multi-antigen vaccineHIV-1 polyvalent antigensGag/Pol/Nef/Env complexHIV-1 therapeutic vaccine antigens

Induction of HIV-specific cellular (CD8+ and CD4+ T-cell) and humoral (antibody) immune responses to recognize and eliminate HIV-infected cells or neutralize free virions (PubMed: 19027482).